&nbsp;

Sep 2025

Drug

lomustine

Other Name(s): CeeNU®

Quick Link(s):

Aug 2024

Drug

nelarabine

Other Name(s): Atriance®

Quick Link(s):

Apr 2024

Drug

lenvatinib

Other Name(s): Lenvima®

Quick Link(s):

Sep 2023

Drug

lanreotide

Other Name(s): Somatuline® Autogel®

Quick Link(s):

Jun 2024

Drug

liposomal irinotecan

Other Name(s): Onivyde® (Baxalta Canada)

Quick Link(s):

Sep 2017

Regimen

LETR

Cancer Type:

Breast

Intent: Adjuvant

Funding:

ODB - General Benefit

letrozole

Drugs Used:

letrozole

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

NPAC

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

Drugs Used:

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

LETR

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

letrozole

Drugs Used:

letrozole

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

LENA

Cancer Type:

Hematologic,

Myelodysplastic Syndrome (MDS)

Intent: Palliative

Funding:

ODB Limited Use

lenalidomide - For the treatment of patients with anemia due to myelodysplastic syndrome (MDS), according to clinical criteria

Drugs Used:

lenalidomide

Quick Link(s):

Regimen Monograph

May 2022

Regimen

LOMU

Cancer Type:

Central Nervous System

Intent: Palliative

Funding:

ODB - General Benefit

lomustine

Drugs Used:

lomustine

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

NILO

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

niLOtinib - Chronic phase Ph+ CML, with specific criteria

Exceptional Access Program

niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria

Drugs Used:

niLOtinib